On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
An investigational compound with FDA-identified safety uncertainties.
Proposed lipid pathway
The mouse work linked effects to altered beta-adrenergic receptor expression, while finding that the acute action was not simply direct activation of that receptor. [1]
What the evidence shows
What animal experiments found
In obese mice, repeated AOD9604 exposure reduced body weight and fat in a 2001 experiment. Investigators also examined genetically altered mice to explore beta-adrenergic signaling. [1]
What the experiment cannot answer
The experiment measured mouse metabolism. It does not demonstrate reliable human fat loss, tissue repair, or a safe long-term regimen. [1]
What remains unknown
Human benefit cannot be inferred from a growth-hormone fragment name, and safety cannot be assumed from an absence of full-hormone effects.
Safety
FDA assessment
FDA flags immune-response and impurity concerns for AOD-9604, limited safety information, and serious events with uncertain causality. [2]
Route matters
The mouse experiment used intraperitoneal administration. It does not establish equivalent exposure from oral or subcutaneous commercial preparations. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is it equivalent to prescribed growth hormone?
No. A fragment has a different identity and evidence base from a full-length replacement medicine.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice2001 · Primary research · PubMed
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · Compound-specific safety assessment
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.